

THERAVANCE INC  
Form 8-K  
February 16, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **February 16, 2012**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer Identification Number)

**901 Gateway Boulevard**

Edgar Filing: THERAVANCE INC - Form 8-K

South San Francisco, California 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

*The information contained in this Item 7.01 and in the accompanying exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

On February 16, 2012, Theravance, Inc. (the Company ) will present at an investor conference ~~the~~ positive topline results from a Phase 2b efficacy and safety study of GSK961081 ( 081) administered once daily or twice daily for 28 days to 436 patients with moderate to severe chronic obstructive pulmonary disease (COPD). 081, previously known as TD-5959, is an investigational inhaled compound that is a single molecule functioning as both a muscarinic antagonist and a beta2 receptor agonist (MABA). 081 was discovered by Theravance and is currently being developed by GlaxoSmithKline (GSK) under license from Theravance. Progression into Phase 3 development is dependent upon successful completion of ongoing Phase 3-enabling studies. Members of the Company s management will discuss the results and present a slide presentation at the Leerink Swann Healthcare Conference, New York, at 9:30 a.m. Eastern Standard Time.

A copy of the slide presentation is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Slide Presentation at Leerink Swann Healthcare Conference Dated February 16, 2012

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: February 16, 2012

By:

*/s/ Michael W. Aguiar*  
**Michael W. Aguiar**  
**Chief Financial Officer**

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Slide Presentation at Leerink Swann Healthcare Conference Dated February 16, 2012